Table 3.
Characteristics of Patients Treated With Sofosbuvir and Ribavirin With and Without Pegylated Interferon
| Variable | SOF-PEG-RBV (N=12) | SOF-RBV (N=2) |
|---|---|---|
| Age, yrs | 60.7 | 70.5 |
| Sex | ||
| Male | 11 | 2 |
| Female | 1 | 0 |
| Race (%) | ||
| Black | 25% | 50% |
| Body Mass Index (%) | ||
| >30 | 25% | 50% |
| Genotype | ||
| 1a | 9 | 2 |
| 1b | 3 | 0 |
| Cirrhosis (%) | 67% | 50% |
| Fibrosis Stage | ||
| F1 | 0 | 0 |
| F2 | 1 | 1 |
| F3 | 2 | 0 |
| F4 | 8 | 1 |
| Not assessed | 1 | 0 |
| Special Populations (%) | ||
| Coinfection | 8% | 0% |
| OLT | 8% | 50% |
| HCC | 0% | 0% |
HCC, hepatocellular carcinoma; OLT, orthotopic liver transplantation; SOF-PEG-RBV, sofosbuvir, pegylated interferon, and ribavirin; SOF-RBV, sofosbuvir and ribavirin.